Madeleine Pettersson Bergstrand

Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays

Madeleine Pettersson Bergstrand, Anders Helander, Therése Hansson et al. · Drug Testing and Analysis · 2016 · 89 citations

Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine

Madeleine Pettersson Bergstrand, Anders Helander, Olof Beck · Journal of Chromatography B · 2016 · 66 citations

Gas Chromatography, Medicine, Drug Purity +12

Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes

Markus R. Meyer, Madeleine Pettersson Bergstrand, Anders Helander et al. · Analytical and Bioanalytical Chemistry · 2016 · 63 citations

Medicinal Chemistry, Drug Testing Purposes, Pharmaceutical Science +11

Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project

Matilda Bäckberg, Madeleine Pettersson Bergstrand, Olof Beck et al. · Clinical Toxicology · 2018 · 55 citations

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Lea Wagmann, Lilian H.J. Richter, Tobias Kehl et al. · Analytical and Bioanalytical Chemistry · 2019 · 53 citations · Full text

Substance Abuse, Psychoactive Drug, Medicine +10